OBJECTIVE: Hepatotoxicity is a significant complication of antiretroviral therapy (ART). We assessed the incidence of and risk factors for hepatotoxicity among HIV-infected individuals on ART in South Africa. DESIGN: We conducted a retrospective cohort study in a workplace HIV care program in South Africa which uses a first-line regimen of efavirenz, zidovudine, and lamivudine and provides routine clinical and laboratory monitoring. METHODS: We included subjects with baseline and follow-up alanine transaminase and aspartate aminotransferase tests. Severe hepatotoxicity cases were identified during the first 12 months of ART. Potential risk factors, including concomitant medication use, tuberculosis, and hepatitis B and C, were determined from clinical records, database queries, and serological testing. Associations with hepatotoxicity were investigated using Cox proportional hazards modeling. RESULTS: Of the 868 subjects (94% male, median age 41 years), the median nadir CD4 cell count was 136/microl, 25% received concomitant tuberculosis treatment during ART, and 17% of a randomly selected subset were positive for hepatitis B surface antigen (HBsAg). We identified 7.7 episodes of severe hepatotoxicity per 100 person-years. Tuberculosis treatment increased risk 8.5 fold, positive HBsAg 3.0 fold, and nadir CD4 cells count < 100/microl 1.9 fold. Importantly, the fraction of patients with severe hepatotoxicity on ART (4.6%) was similar to the fraction with liver enzyme elevations > 5 times the upper limit of normal before starting ART (4%). CONCLUSIONS: In this African ART cohort, we found a low incidence of and minimal morbidity due to hepatotoxicity. HBsAg and concomitant tuberculosis therapy significantly increased the risk of hepatotoxicity.
OBJECTIVE: Hepatotoxicity is a significant complication of antiretroviral therapy (ART). We assessed the incidence of and risk factors for hepatotoxicity among HIV-infected individuals on ART in South Africa. DESIGN: We conducted a retrospective cohort study in a workplace HIV care program in South Africa which uses a first-line regimen of efavirenz, zidovudine, and lamivudine and provides routine clinical and laboratory monitoring. METHODS: We included subjects with baseline and follow-up alanine transaminase and aspartate aminotransferase tests. Severe hepatotoxicity cases were identified during the first 12 months of ART. Potential risk factors, including concomitant medication use, tuberculosis, and hepatitis B and C, were determined from clinical records, database queries, and serological testing. Associations with hepatotoxicity were investigated using Cox proportional hazards modeling. RESULTS: Of the 868 subjects (94% male, median age 41 years), the median nadir CD4 cell count was 136/microl, 25% received concomitant tuberculosis treatment during ART, and 17% of a randomly selected subset were positive for hepatitis B surface antigen (HBsAg). We identified 7.7 episodes of severe hepatotoxicity per 100 person-years. Tuberculosis treatment increased risk 8.5 fold, positive HBsAg 3.0 fold, and nadir CD4 cells count < 100/microl 1.9 fold. Importantly, the fraction of patients with severe hepatotoxicity on ART (4.6%) was similar to the fraction with liver enzyme elevations > 5 times the upper limit of normal before starting ART (4%). CONCLUSIONS: In this African ART cohort, we found a low incidence of and minimal morbidity due to hepatotoxicity. HBsAg and concomitant tuberculosis therapy significantly increased the risk of hepatotoxicity.
Authors: P Ocama; B Castelnuovo; M R Kamya; G D Kirk; S J Reynolds; A Kiragga; R Colebunders; D L Thomas Journal: Int J STD AIDS Date: 2010-08 Impact factor: 1.359
Authors: Elin Svensson; Jan-Stefan van der Walt; Karen I Barnes; Karen Cohen; Tamara Kredo; Alwin Huitema; Jean B Nachega; Mats O Karlsson; Paolo Denti Journal: Br J Clin Pharmacol Date: 2012-09 Impact factor: 4.335
Authors: Christopher J Hoffmann; Katherine L Fielding; Salome Charalambous; Mark S Sulkowski; Craig Innes; Chloe L Thio; Richard E Chaisson; Gavin J Churchyard; Alison D Grant Journal: AIDS Date: 2008-01-02 Impact factor: 4.177
Authors: Nimzing G Ladep; Olufunmilayo A Lesi; Pantong Mark; Maud Lemoine; Charles Onyekwere; Mary Afihene; Mary Me Crossey; Simon D Taylor-Robinson Journal: World J Hepatol Date: 2014-11-27
Authors: Jules B Tchatchueng Mbougua; Christian Laurent; Charles Kouanfack; Anke Bourgeois; Laura Ciaffi; Alexandra Calmy; Henri Gwet; Sinata Koulla-Shiro; Jacques Ducos; Eitel Mpoudi-Ngolé; Nicolas Molinari; Eric Delaporte Journal: BMC Public Health Date: 2010-03-01 Impact factor: 3.295